Acquisition by Denner Alexander J of 1359 shares of Ironwood Pharmaceuticals subject to Rule 16b-3
IRWD Stock | USD 3.53 0.03 0.84% |
About 62% of Ironwood Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Ironwood Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Ironwood Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Ironwood Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Ironwood |
Filed transaction by Ironwood Pharmaceuticals Director, 10 Percent Owner . Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Ironwood Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Ironwood Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Ironwood Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Ironwood Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ironwood Pharmaceuticals Fundamental Analysis
We analyze Ironwood Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ironwood Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ironwood Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Ironwood Pharmaceuticals is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Ironwood Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ironwood Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Ironwood Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ironwood Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Ironwood Pharmaceuticals Related Equities
AVDL | Avadel Pharmaceuticals | 5.20 | ||||
NBIX | Neurocrine Biosciences | 5.01 | ||||
ESPR | Esperion Therapeutics | 3.56 | ||||
ITCI | Intracellular | 2.51 | ||||
ASRT | Assertio Therapeutics | 2.17 | ||||
COLL | Collegium Pharmaceutical | 2.09 | ||||
ALKS | Alkermes Plc | 0.52 | ||||
PCRX | Pacira BioSciences, | 0.05 | ||||
ANIP | ANI Pharmaceuticals | 0.41 | ||||
AMPH | Amphastar | 3.31 |
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |